VCs provide $40M to finance Celator’s pivotal PhIII AML study

John Carroll Princeton, NJ-based Celator Pharmaceuticals has raised close to $ 40 million, enough to get its lead cancer drug–a reformulation of standard drugs infused in nano-sized ...

Vertex skyrockets on positive Ph2 combo study in cystic fibrosis

Ryan McBride Vertex Pharmaceuticals ($ VRTX) jolted Wall Street with a fresh batch of midstage data on one of its combo therapies against cystic fibrosis. The biotech powerhouse tested ...

Report slams FDA’s response to CRO’s fraudulent study data

Ryan McBride The FDA is feeling the sting from defunct Cetero Research's fraudulent drug trial data nearly three years after investigators raided the CRO's Houston labs. ProPublica ...

U.S. adults still skipping pills to save money, CDC study finds

Tracy Staton Medicare Part D keeps patients on their meds. That's the upside of a new study that shows U.S. adults are still skipping doses to save money. And patients who don't ...

Pharma reps aren’t talking about drug risks, study finds

Tracy Staton Doctors aren't getting the skinny on drug side effects from pharma reps, a new study finds. Even the most serious risks are often overlooked, the survey found. And ...
Page 13 of 13« First...910111213
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS